Science Explorer Back to mapMap

Most cited papers from Puerto Rico Community Foundation

What are the most cited papers from Puerto Rico Community Foundation?

The most cited paper from Puerto Rico Community Foundation is "Treatment of HCV Infection by Targeting MicroRNA" (Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz et al., 2013), with 2,233 citations. Next come "Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection" (1,794) and "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib" (1,243).

Showing 50 of 60 papers. Every paper with more than 33 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Treatment of HCV Infection by Targeting MicroRNA Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz et al. · New England Journal of Medicine Open access 27 Mar 2013 2,233
2 Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection Eric Lawitz et al. · New England Journal of Medicine 23 Apr 2013 1,794
3 Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Thomas C. C. Yau et al. · JAMA Oncology Open access Oct 2020 1,243
4 Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients Francesca J. Torriani, Maribel Rodriguez‐Torres, Jürgen Kurt Rockstroh et al. · New England Journal of Medicine Open access 28 Jul 2004 1,238
5 Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski et al. · New England Journal of Medicine 15 Jan 2014 1,197
6 Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson et al. · New England Journal of Medicine Open access 23 Apr 2013 1,093
7 All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson et al. · Hepatology Open access 23 Jan 2015 694
8 Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C John G. McHutchison, Geoffrey M Dusheiko, Mitchell L. Shiffman et al. · New England Journal of Medicine 28 Nov 2007 451
9 Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Eric Lawitz et al. · The Lancet Infectious Diseases 15 Mar 2013 331
10 Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection Mark Sulkowski, Susanna Naggie, Jacob Paul Lalezari et al. · JAMA Open access 19 Jul 2014 254
11 CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis Masatoshi Kudo, Ana María Matilla, Armando Santoro et al. · Journal of Hepatology Open access 26 May 2021 234
12 Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients Meike H. van der Ree, Adriaan J. van der Meer, Joep de Bruijne et al. · Antiviral Research 8 Sep 2014 202
13 Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection Gregory T. Everson et al. · Gastroenterology Open access 30 Oct 2013 199
14 Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C Maribel Rodriguez‐Torres, Lennox J. Jeffers, Muhammad Y. Sheikh et al. · New England Journal of Medicine 14 Jan 2009 182
15 Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Richard E. Nettles, Min Gao, Marc Bifano et al. · Hepatology Open access Dec 2010 177
16 A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection Andrew Joseph Muir et al. · Journal of Hepatology 23 Jul 2014 147
17 High-resolution mapping of forest carbon stocks in the Colombian Amazon Gregory P. Asner, John K. Clark, Joseph Mascaro et al. · Biogeosciences Open access 25 Jul 2012 144
18 Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy Nezam H. Afdhal, Geoffrey M Dusheiko, Edoardo Giovanni Giannini et al. · Gastroenterology Open access 11 Oct 2013 143
19 Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients Eric Lawitz, Maribel Rodriguez‐Torres, Andrew Joseph Muir et al. · Journal of Hepatology 30 Apr 2008 128
20 Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis Paul J. Pockros, Lennox J. Jeffers, Nezam H. Afdhal et al. · Hepatology Open access 26 Feb 2007 112
21 Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial Maribel Rodriguez‐Torres, Eric Lawitz, Kris V. Kowdley et al. · Journal of Hepatology 23 Nov 2012 107
22 High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials Patrick Marcellin, Hugo Cheinquer, Manuela Curescu et al. · Hepatology 18 Jun 2012 105
23 R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin† Paul J. Pockros, David R. Nelson, Eliot W. Godofsky et al. · Hepatology Open access 20 Jun 2008 101
24 Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection Fred F Poordad et al. · JAMA 5 May 2015 95
25 Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 Ignacio Melero et al. · Annals of Oncology Open access 22 May 2024 94
26 Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3 David R. Nelson, Yves Benhamou, Wan‐Long Chuang et al. · Gastroenterology Open access 2 Jul 2010 93
27 Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection John G. McHutchison, Zachary D Goodman, Keyur Patel et al. · Gastroenterology Open access 17 Dec 2009 93
28 Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels Mitchell L. Shiffman, M. Diago, Albert Tran et al. · Clinical Gastroenterology and Hepatology May 2006 91
29 Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 Alexander J. V. Thompson, Keyur Patel, Wan‐Long Chuang et al. · Gut Open access 26 Aug 2011 89
30 Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics Michael Fried, Donald M. Jensen, Maribel Rodriguez‐Torres et al. · Hepatology Open access 9 Jun 2008 77
31 Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin Norbert Bräu, Maribel Rodriguez‐Torres, Dale Prokupek et al. · Hepatology Open access 26 Mar 2004 74
32 Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial Thomas C. C. Yau, Vittorina Zagonel, Armando Santoro et al. · Journal of Clinical Oncology Open access 13 Dec 2022 70
33 Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive A 16-Week Abbreviated Course of Peginterferon Alfa-2A (40Kd) Plus Ribavirin M. Diago, Mitchell L. Shiffman, Jean–Pierre Bronowicki et al. · Hepatology Open access 27 Jan 2010 68
34 Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial Maribel Rodriguez‐Torres, Jihad Slim, Laveeza Bhatti et al. · HIV Clinical Trials Open access Jun 2012 65
35 Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1 Stefan Zeuzem, Mark Sulkowski, Eric Lawitz et al. · Gastroenterology 2 Jul 2010 64
36 Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial Edward John Gane et al. · Gastroenterology Open access 31 Jul 2016 60
37 A phase 1, randomized, dose‐ranging study of GS ‐5816, a once‐daily NS 5A inhibitor, in patients with genotype 1–4 hepatitis C virus Eric Lawitz, Bradley Freilich, John O. Link et al. · Journal of Viral Hepatitis Open access 16 Jul 2015 58
38 Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study Michael Peter Manns, Edward John Gane, Maribel Rodriguez‐Torres et al. · Hepatology Open access 3 Apr 2012 58
39 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL Peter Ferenci et al. · Journal of Hepatology Apr 2013 54
40 A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma Tudor–Eliade Ciuleanu, Igor S. Bazin, Dan Lungulescu et al. · Annals of Oncology Open access 23 Jan 2016 52
41 Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ) David R. Nelson, Stefan Zeuzem, Pietro Andreoné et al. · Annals of Hepatology Open access 2012 52
42 Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C Claudio Pasquinelli et al. · Antimicrobial Agents and Chemotherapy Open access 31 Jan 2012 51
43 Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938 Jérémie Guedj, Phillip S. Pang, Jill Denning et al. · Antiviral Therapy 24 Jan 2014 50
44 Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients Patrick Marcellin, Robert G. Gish, Norman Gitlin et al. · Journal of Hepatology 24 Oct 2009 46
45 All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection David L. Wyles, Maribel Rodriguez‐Torres, Eric Lawitz et al. · Hepatology Open access 5 Feb 2014 45
46 Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population Maribel Rodriguez‐Torres, Mark Sulkowski, Raymond T. Chung et al. · Journal of Viral Hepatitis Open access 6 Aug 2009 44
47 Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients Heiner H. Wedemeyer, Donald M. Jensen, Robert Herring et al. · Hepatology 24 Jan 2013 43
48 Effect of Cryopreservation on Human Articular Chondrocyte Viability, Proliferation, and Collagen Expression E. Rendal, Emilia Maneiro-Pampı́n, M. Rodríguez-Cabarcos et al. · Cryobiology Feb 2001 42
49 Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study Maribel Rodriguez‐Torres, Francesca J. Torriani, Vincent Soriano et al. · Antimicrobial Agents and Chemotherapy Open access 27 Sep 2005 41
50 High Eradication Rates of Helicobacter pylori Infection with First- and Second-Line Combination of Esomeprazole, Tetracycline, and Metronidazole in Patients Allergic to Penicillin Maribel Rodr�guez-Torres, Rosa Salgado-Mercado, Carlos F. R�os-Bedoya et al. · Digestive Diseases and Sciences 31 Mar 2005 41

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.